Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN L A versus PEN VEE K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN L A versus PEN VEE K.
BICILLIN L-A vs PEN-VEE K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
250-500 mg orally every 6-8 hours for mild to moderate infections; up to 2 g/day for severe infections.
None Documented
None Documented
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
Terminal elimination half-life: 30-60 minutes in adults with normal renal function, prolonged to 3-10 hours in severe renal impairment.
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 60-90% of elimination; biliary/fecal elimination is minimal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic